Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study;Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España

Revista Espanola de Cardiologia

Volumn 64, Issue 4, 2011, Pages 286-294

  González Juanatey, José R ^a   Millán, Jesús ^b   Alegría, Eduardo ^c   Guijarro, Carlos ^d   Lozano, Jose V ^e   Vitale, Gustavo C ^f  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^e Centro de Salud Nazaret   (Spain)

^f Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

Cardiovascular prevention; DYSIS; High density lipoprotein cholesterol; Low density lipoprotein cholesterol; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PRIMARY PREVENTION; SECONDARY PREVENTION; SPAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79953280607     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2010.10.030     Document Type: Article

References (40)

1. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2007;28:2375-414.
2. Cordero A, Bertomeu V, Mazón P, Quiles J, Aznar J, Bueno H. Diferences in medical treatment of chronic coronary heart disease patients according to medical specialities. Cardiovasc Ther. 2009;27:173-80.
3. Gabriel R, Alonso M, Segura A, Tormo MJ, Artigao LM, Banegas JR, et al. Prevalencia, distribución y variabilidad geográfica de los principales factores de riesgo cardiovascular en España. Análisis agrupado de datos individuales de estudios epidemiológicos poblacionales: estudio ERICE. Rev Esp Cardiol. 2008;61:1030-40.
4. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation. 2003;108:1541-5. (Pubitemid 37187777)
5. Yusuf S, Hawken S, Ounpuu S, Dans T, Avenzum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364: 937-52. (Pubitemid 39208455)
6. Medrano MJ, Pastor R, Boix R, Del Barrio JL, Damián J, Álvarez R, et al. Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española. Rev Esp Cardiol. 2007;60:1250-6. (Pubitemid 350294324)
7. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512-15124.
8. Baigent C, Keech A, Kearney PM, BlacKwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
9. Lee JMS, Choudhury RP. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart. 2007;93:559-64. (Pubitemid 46707106)
10. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High BloodCholesterol in Adults (Adult Treatment Panel III). JAMA.2001;285:2486-97.
11. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143.
12. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15. (Pubitemid 19043669)
13. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS). BMJ. 1998;316:823-8. (Pubitemid 28112428)
14. Cea-Calvo L, Lozano JV, Fernández-Pérez C, Llisterri JL, Martí-Canales JC, Aznar J, et al. Prevalence of low HLD cholesterol, and relationship between serum HDL and cardiovascular disease in elderly Spanish population: the PREV-ICTUS Study. Int J Clin Prac. 2009;63:71-81.
15. González-Juanatey JR, Grigorian L, Juiz MA, Sánchez M, Rodríguez E, Dopico J, et al. Impacto pronóstico de la localización de la enfermedad aterosclerosa previa en pacientes diabéticos. Estudio Barbanza-Diabetes. Rev Esp Cardiol. 2008;61:1168-77.
16. Gitt AK, Kastelein JP. High prevalence of dyslipidemia in 18,574 patients treated with statins in Europe and Canada: Results of the dyslipidemia international study. Eur Heart J. 2009;30 Suppl1:303.
17. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med. 2006;38:34-41. (Pubitemid 43177786)
18. Grant RW, Meigs JB. Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction. Diabetes Care. 2007;30:479-84. (Pubitemid 46354321)
19. Goff Jr DC, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, et al. Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation. 2006;113:647-56.
20. Daly CA, Clemens F, López-Sendón JL, Tavazzi L, Boersma E, Danchin N, et al. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J. 2006;27:1298-304. (Pubitemid 43998102)
21. Nichols GA, Nag S, Chan W. Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update. Am Heart J. 2007;154:554-60.
22. Assmann G, Benecke H, Neiss A, Cullen P, Schulte H, Bestehorn K. Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil. 2006;13:776-83. (Pubitemid 44454851)
23. Persell SD, Lloyd-Jones DM, Baker DW. Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. J Gen Intern Med. 2006;21:171-6. (Pubitemid 43363674)
24. Ose L, Skjeldestad FE, Bakken IJ, Levorsen A, Alemao EA, Yin DD, et al. Lipid management and cholesterol goal attainment in Norway. Am J Cardiovasc Drugs. 2006;6:121-8.
25. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J. 2008;156:112-9.
26. NCEP-ATP III Guidelines At-A-Glance Quick Desk Reference. Disponible en: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf
27. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81:582-7. (Pubitemid 28182422)
28. Leitersdorf E. Cholesterol absorption inhibition: filling an unmet need in lipid lowering management. Eur Heart J Suppl. 2001;3 Suppl E:E17-23.
29. Sharrett AR, Ballantyne CM, Coady SA, Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001;104:1108-13. (Pubitemid 32830392)
30. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med. 1991;325:373-81.
31. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol. 1992;70:733-7.
32. Assmann G, Schulte H, Von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis. 1996;124:S11-20.
33. Wild S, Byrne CD. Time to rethink high-density lipoprotein? Heart. 2008;94:692-4.
34. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation. 2004;109:42-6. (Pubitemid 38056019)
35. Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499-501. (Pubitemid 350050854)
36. Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil. 2009;16:438-44.
37. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-83. (Pubitemid 44128440)
38. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459-67.
39. Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, et al. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation. 2005;111:488-93. (Pubitemid 40204434)
40. Davidson MH, Maki KC, Pearson TA, Deedwania PC, McKenney JM, Fonarow GC, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005;96:556-63. (Pubitemid 41132774)